Indianapolis, Indiana, U.S., September 24, 2026
Eli Lilly and Company has reached a major milestone in diabetes care following U.S. Food and Drug Administration (FDA) approval of Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection for adults living with type 2 diabetes. The treatment is approved as an adjunct to diet and exercise to improve glycemic control and is designed to provide basal insulin coverage across a full seven-day dosing interval. The approval introduces another option for adults who require basal insulin and represents a significant development in the ongoing effort to reduce the treatment burden associated with frequent insulin injections.
FDA Approves Once-Weekly Basal Insulin
Onswik is a long-acting insulin analog administered by subcutaneous injection once each week on the same day. Unlike conventional daily basal insulin regimens, the product is designed to maintain insulin activity over seven days. Lilly estimates that the once-weekly schedule can reduce the number of basal-insulin injections by more than 300 injections per year compared with once-daily basal insulin, although this comparison is about dosing frequency and does not represent a comparison of safety or efficacy. The FDA approval applies specifically to adults with type 2 diabetes mellitus. Onswik is not recommended for people with type 1 diabetes because of an increased risk of severe hypoglycemia. The FDA describes Onswik as the second once-weekly insulin approved for adults with type 2 diabetes, adding a new dosing approach to the available insulin-treatment landscape.
Phase 3 QWINT Program Supported Approval
The regulatory decision was supported by Lilly’s QWINT Phase 3 clinical development program, which evaluated once-weekly insulin efsitora alfa in more than 3,400 adults with type 2 diabetes across four registration studies. The trials included participants who were insulin-naive as well as adults already receiving basal insulin or basal and mealtime insulin. Across the QWINT program, Onswik was compared with commonly used daily basal insulins, including insulin glargine U-100 and insulin degludec U-100. The four trials were designed to assess the efficacy and safety of once-weekly efsitora across different treatment settings. According to Lilly and the FDA, Onswik achieved non-inferior reductions in A1C compared with the daily basal insulin comparators in the registration studies. The FDA likewise reported that Onswik reduced hemoglobin A1C, a measure of average blood glucose levels over time, to a similar extent as insulin glargine and insulin degludec in the four randomized studies.
Advertisement
Safety Profile and U.S. Availability
The overall safety profile observed in the clinical program was described as similar to the daily basal insulins studied. The FDA identifies hypoglycemia as the most common adverse reaction associated with Onswik, while other reported adverse reactions include hypersensitivity reactions, injection-site reactions, lipodystrophy, itching, rash, edema and weight gain. The prescribing information also contains warnings concerning severe hypoglycemia, medication errors, accidental overdose and other potential risks. Lilly plans to make Onswik KwikPen available in the United States in two concentrations, 500 units/mL and 1,000 units/mL. The product is administered once weekly, and patients are instructed to follow their healthcare provider’s prescribed dosing schedule. The FDA-approved labeling also provides instructions for changing the weekly injection day and handling a missed dose.
The U.S. approval follows regulatory actions in other markets, making the FDA decision the fourth global approval for Onswik for adults with type 2 diabetes, according to Lilly. With its once-weekly administration and Phase 3 clinical evidence, Onswik expands Lilly’s diabetes portfolio with a new basal-insulin dosing option for adults who require insulin therapy.
Source: Eli Lilly press release
